Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15422359 | 1.00 | TGFBR1 (0.35) | TGFBR1ALDH1A1TDP1KDM4E | |
| SCHEMBL9550398 | 0.88 | TGFBR1 (0.39) | TGFBR1ALDH1A1TDP1KDM4E | |
| SCHEMBL10407850 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL10407848 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL28328511 | 0.81 | — | — | |
| SCHEMBL15014686 | 0.81 | — | — | |
| SCHEMBL491406 | 0.80 | ALDH1A1 (0.43) | TGFBR1ALDH1A1TDP1 | |
| SCHEMBL491408 | 0.80 | ALDH1A1 (0.43) | TGFBR1ALDH1A1TDP1 | |
| SCHEMBL19076272 | 0.80 | ALDH1A1 (0.36) | TGFBR1ALDH1A1 | |
| SCHEMBL4591815 | 0.77 | ALDH1A1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108923-B2 | Compounds, compositions, and methods for cancer therapy | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140024639-A1 | Compounds, Compositions, and Methods for Cancer Therapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024639-A1 | Compounds, Compositions, and Methods for Cancer Therapy | MCL1, TP53, VHL | TGFBR1 4137/4885ALDH1A1 710/4885TDP1 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.